Iron supplementation in a large Swiss cohort of IBD patients demonstrates a shift from oral to intravenous iron over time
Details
Serval ID
serval:BIB_8475E046BCAF
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Poster: Summary – with images – on one page of the results of a researche project. The summaries of the poster must be entered in "Abstract" and not "Poster".
Collection
Publications
Institution
Title
Iron supplementation in a large Swiss cohort of IBD patients demonstrates a shift from oral to intravenous iron over time
Title of the conference
7th Congress of ECCO, European Crohn's and Colitis Organisation
Address
Barcelona, Spain, February 16-18, 2012
ISBN
1873-9946
ISSN-L
0021-9355
Publication state
Published
Issued date
2012
Volume
6
Series
Journal of Crohn's and Colitis
Pages
S135
Language
english
Abstract
Background: The 2007 European Crohn's and Colitis Organization
guidelines on anemia in inflammatory bowel disease (IBD)
favour intravenous (iv) over oral (po) iron supplementation due
to better effectiveness and tolerance. We aimed to determine
the percentage of IBD patients under iron supplementation
therapy and the dynamics of prescription habits (iv versus po)
over time.
Methods: Helsana, a leading Swiss health insurance company
provides coverage for approximately 18% of the Swiss
population, corresponding to about 1.2 million enrollees.
Patients with Crohn's disease (CD) and ulcerative colitis (UC)
were analyzed from the anonymised Helsana database.
Results: In total, 629 CD (61% female) and 398 UC (57%
female) patients were identified, mean observation time was
31.8 months for CD and 31.0 months for UC patients. Of the
entire study population, 27.1% were prescribed iron (21.1%
in males and 31.1% in females). Patients treated with IBDspecific
drugs (steroids, immunomodulators, anti-TNF agents)
were more frequently treated with iron compared to patients
without any medication (35.0% vs. 20.9%, OR 1.91, 95%-
CI 1.41 2.61). The prescription of iv iron increased from
2006/2007 (48.8% of all patients receiving any iron priscription)
to 65.2% in 2008/2009 by a factor of 1.89.
Conclusions: One third of the IBD population was treated
with iron supplementation. A gradual shift from oral to iv iron
was observed over time. This switch in prescription habits
goes along with the implementation of the ECCO consensus
guidelines on anemia in IBD.
guidelines on anemia in inflammatory bowel disease (IBD)
favour intravenous (iv) over oral (po) iron supplementation due
to better effectiveness and tolerance. We aimed to determine
the percentage of IBD patients under iron supplementation
therapy and the dynamics of prescription habits (iv versus po)
over time.
Methods: Helsana, a leading Swiss health insurance company
provides coverage for approximately 18% of the Swiss
population, corresponding to about 1.2 million enrollees.
Patients with Crohn's disease (CD) and ulcerative colitis (UC)
were analyzed from the anonymised Helsana database.
Results: In total, 629 CD (61% female) and 398 UC (57%
female) patients were identified, mean observation time was
31.8 months for CD and 31.0 months for UC patients. Of the
entire study population, 27.1% were prescribed iron (21.1%
in males and 31.1% in females). Patients treated with IBDspecific
drugs (steroids, immunomodulators, anti-TNF agents)
were more frequently treated with iron compared to patients
without any medication (35.0% vs. 20.9%, OR 1.91, 95%-
CI 1.41 2.61). The prescription of iv iron increased from
2006/2007 (48.8% of all patients receiving any iron priscription)
to 65.2% in 2008/2009 by a factor of 1.89.
Conclusions: One third of the IBD population was treated
with iron supplementation. A gradual shift from oral to iv iron
was observed over time. This switch in prescription habits
goes along with the implementation of the ECCO consensus
guidelines on anemia in IBD.
Open Access
Yes
Create date
14/02/2013 17:50
Last modification date
20/08/2019 15:44
Usage data
